Standard dose anthracycline plus all-trans retinoic acid and arsenic trioxide as induction chemotherapy significantly reduces early death and relapse for high-risk acute promyelocytic leukemia: a single-center real-world analysis.

ABSTRACT:

Background

All-trans retinoic acid (ATRA) and arsenic trioxide (ATO) have revolutionized the treatment of acute promyelocytic leukemia (APL). However, the management of high-risk APL has not been conclusively established. The optimal dosage of anthracycline in the induction has long been debated when ATO is added.

Objectives

To explore the management of high-risk APL regarding the optimal dosage of anthracycline in the induction and the predicators of prognosis.

Design

This was a retrospective study in the real-world setting.

Methods

High-risk APL patients defined as white blood cell (WBC) greater than 10 × 10⁹/L who received ATO-based induction regimens were included. Data on clinical characteristics, treatment regimens, and prognosis including earl

SUBMITTER: Shen K 

PROVIDER: S-EPMC11577467 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature